India, June 18 -- The U.S. Food and Drug Administration announced launch of a new program to issue Commissioner's National Priority Vouchers or CNPVs, which shortens review time significantly, with a view to support national health priorities. The new CNPV program, which will begin in 2025, aims to accelerate the drug review process for companies while maintaining the FDA's rigorous standards for safety, efficacy, and quality.
The agency noted that the new voucher may be redeemed by drug developers to participate in a novel priority program by the FDA that shortens its review time to 1-2 months from around 10-12 months, following a sponsor's final drug application submission.
The new CNPV process convenes experts from FDA offices for a te...